Expression of potential biomarkers associated with homologous recombination repair in patients with ovarian or triple-negative breast cancer

Hiroyuki Nomura, Fumio Kataoka, Daisuke Aoki, Hiromitsu Jinno, Yuukou Kitagawa, Yuji Sato, Chris Womack, Helen Wombwell, Darren Hodgson, Mark O'Connor, Chris Harbron, Xiaolu Yin

Research output: Contribution to journalArticle

4 Citations (Scopus)


BACKGROUND: Poly(ADP)-ribose polymerase (PARP) inhibitors such as olaparib can induce cell death in cancer cells with homologous recombination (HR) DNA repair deficiencies, such as BRCA1/2 mutations. AIM: To identify prognostic biomarkers of long-term outcomes in cancer patients. METHODS: Immunohistochemistry was used to analyse expression of key HR pathway proteins (ATM, ATR, BRCA1, MDC1, MRE11) and PARP-1 in 100 serous ovarian cancer (SOC) and 100 triple-negative breast cancer (TNBC) tumour samples from Japanese patients. RECIST assessment was used. RESULTS: Patient demographic data and BRCA1/2 mutation status were unavailable. Most proteins listed previously were detected in > 80% of tissue samples, with BRCA1 expression detected in 60-65%. A potential link between BRCA1 expression and overall survival (M stage adjusted) in SOC patients was observed, but was not statistically significant after multiple testing adjustment. Correlations between other biomarker expression and survival were not observed. In TNBC patients, MDC1 staining was associated with progressive disease, but this was not statistically significant; the analysis did not identify significant correlations between biomarker expression and disease control. Limited event numbers prevented assessment of the prognostic value of BRCA1 in TNBC. CONCLUSION: BRCA1 expression may be a candidate for a prognostic biomarker in SOC. Further studies are warranted.

Original languageEnglish
Pages (from-to)145-152
Number of pages8
JournalCancer Biomarkers
Issue number1
Publication statusPublished - 2016 Jan 18



  • Biomarker
  • BRCA
  • Breast cancer
  • Ovarian cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Genetics

Cite this